Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIREFLEYE: intravitreal aflibercept versus laser photocoagulation for retinopathy of prematurity
MOH_2019-07-08_007180Phase 3Completed
- Sponsor
- Bayer
- Start
- Jun 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aflibercept in retinopathy of prematurity (ROP) (2 arms), sponsored by Bayer. Started Jun 2019; status: completed.
02
Drugs
aflibercept
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on MOH_2019-07-08_007180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-07-08_007180.